ENvue Medical entered into a committed equity facility allowing it to sell up to $50 million of common stock at 90% of the three-day VWAP, with proceeds earmarked for Series X Preferred Stock redemption and working capital. Simultaneously, the company amended its July 2025 Series H Preferred Stock purchase agreement to increase total additional investment rights to a $59 million stated value, contingent on shareholder approval. The investor must exercise at least $10 million within twelve months of approval, with monthly minimums of approximately $833,333. ENvue Medical operates in the healthcare technology sector, providing practice management software for medical groups.
